Cabaletta Bio Inc
CABA1.515USD
+0.075+5.21%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
76.88MCap. mercado
PérdidaP/E TTM
Más Datos de Cabaletta Bio Inc Compañía
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Información de la empresa
Símbolo de cotizaciónCABA
Nombre de la empresaCabaletta Bio Inc
Fecha de salida a bolsaOct 25, 2019
Director ejecutivoDr. Steven Nichtberger, M.D.
Número de empleados161
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 25
Dirección2929 Arch Street
CiudadPHILADELPHIA
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal19104
Teléfono12677593100
Sitio Webhttps://www.cabalettabio.com/
Símbolo de cotizaciónCABA
Fecha de salida a bolsaOct 25, 2019
Director ejecutivoDr. Steven Nichtberger, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Steven Nichtberger, M.D.
Dr. Steven Nichtberger, M.D.
Chief Executive Officer, President, Chairman of the Board, Co-Founder
Chief Executive Officer, President, Chairman of the Board, Co-Founder
1.35M
-30.78%
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Dr. David J. Chang, M.D.
Dr. David J. Chang, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Catherine Bollard, M.D.
Dr. Catherine Bollard, M.D.
Independent Director
Independent Director
--
--
Mr. Mark J. Simon
Mr. Mark J. Simon
Independent Director
Independent Director
--
--
Ms. Shawn Cline Tomasello
Ms. Shawn Cline Tomasello
Independent Director
Independent Director
--
--
Mr. Richard Conover Henriques, Jr.
Mr. Richard Conover Henriques, Jr.
Independent Director
Independent Director
--
--
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
President - Science and Technology
President - Science and Technology
--
--
Dr. Arun Das, M.D.
Dr. Arun Das, M.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Anup Marda
Mr. Anup Marda
Chief Financial Officer
Chief Financial Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Steven Nichtberger, M.D.
Dr. Steven Nichtberger, M.D.
Chief Executive Officer, President, Chairman of the Board, Co-Founder
Chief Executive Officer, President, Chairman of the Board, Co-Founder
1.35M
-30.78%
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Dr. David J. Chang, M.D.
Dr. David J. Chang, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Catherine Bollard, M.D.
Dr. Catherine Bollard, M.D.
Independent Director
Independent Director
--
--
Mr. Mark J. Simon
Mr. Mark J. Simon
Independent Director
Independent Director
--
--
Ms. Shawn Cline Tomasello
Ms. Shawn Cline Tomasello
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 24 de jun
Actualizado: mar., 24 de jun
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Jennison Associates LLC
6.69%
Citadel Advisors LLC
5.36%
T. Rowe Price Investment Management, Inc.
4.41%
Adage Capital Management, L.P.
4.04%
The Vanguard Group, Inc.
3.84%
Other
75.66%
Accionistas
Accionistas
Proporción
Jennison Associates LLC
6.69%
Citadel Advisors LLC
5.36%
T. Rowe Price Investment Management, Inc.
4.41%
Adage Capital Management, L.P.
4.04%
The Vanguard Group, Inc.
3.84%
Other
75.66%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
21.50%
Hedge Fund
13.30%
Investment Advisor/Hedge Fund
9.13%
Research Firm
2.25%
Individual Investor
1.68%
Bank and Trust
0.14%
Pension Fund
0.02%
Other
51.98%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
332
43.19M
48.02%
-20.01M
2025Q1
343
38.78M
72.92%
-24.88M
2024Q4
342
40.39M
82.63%
-20.01M
2024Q3
330
50.24M
102.85%
-12.34M
2024Q2
325
53.21M
110.27%
-11.74M
2024Q1
310
53.11M
110.79%
-5.05M
2023Q4
269
50.62M
118.36%
-623.67K
2023Q3
244
42.61M
108.50%
-4.28M
2023Q2
218
38.30M
97.94%
+637.03K
2023Q1
208
26.57M
91.08%
-5.98M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Jennison Associates LLC
2.43M
2.71%
-78.33K
-3.12%
Mar 31, 2025
Citadel Advisors LLC
4.82M
5.36%
+4.82M
+1376631.43%
Jun 12, 2025
T. Rowe Price Investment Management, Inc.
3.97M
4.41%
-103.98K
-2.55%
Mar 31, 2025
Adage Capital Management, L.P.
3.63M
4.04%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.84M
3.16%
-23.48K
-0.82%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.11M
3.45%
+57.80K
+1.90%
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
2.76M
3.07%
--
--
Mar 31, 2025
Schonfeld Strategic Advisors LLC
1.66M
1.85%
+1.66M
--
Mar 31, 2025
Cantor Fitzgerald, L.P
1.48M
1.65%
+1.38M
+1384.59%
Mar 31, 2025
Nichtberger (Steven)
1.35M
1.5%
-600.00K
-30.78%
Apr 28, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
iShares Morningstar Small-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Humankind US Stock ETF
0%
iShares ESG Aware MSCI USA Small-Cap ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Ver más
iShares Micro-Cap ETF
Proporción0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0%
iShares Russell 2000 ETF
Proporción0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0%
iShares Morningstar Small-Cap ETF
Proporción0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Humankind US Stock ETF
Proporción0%
iShares ESG Aware MSCI USA Small-Cap ETF
Proporción0%
SPDR Portfolio MSCI Global Stock Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
